Analysis of therapeutic effect of cell reduction combined with intraperitoneal thermoperfusion chemotherapy in treatment of peritoneal pseudomyxoma

Table 3 Analysis of factors of incidence of grade III to IV complications in pseudomyxoma of abdominal cavity undergoing cell reduction combined with intraperitoneal

Clinical variables	Cases	Grade III-IV complications incidence rate, n (%)	χ2	P value
Age (years)			0.105	0.746
Up to 60	121	51 (42.1)
Greater than 60	65	29 (44.6)
Gender			0.088	0.766
Male	65	27 (41.5)
Female	121	53 (43.8)
Primary site			2.552	0.225
Appendix	170	71 (41.8)
Ovary	15	9 (9/15)
Other	1	0
Pathological level			0.278	0.598
Low-level	99	46 (46.5)
High level	57	24 (42.1)
Lymph node metastasis			0.349	0.818
Correct	19	8 (8/19)
Deny	151	64 (42.4)
Suspicious transfer	16	8 (8/16)
Peritoneal tumor index score (points)			1.332	0.536
≤ 20	41	16 (39.0)
21-39	111	55 (49.5)
Whether to combine organ resection			14.33	< 0.001
Correct	123	65 (52.8)
Deny	63	15 (23.8)
HIPEC count			4.9	0.298
1	30	17 (56.7)
2	48	16 (33.3)
3	79	34 (43.0)
4	25	12 (48.0)
5	4	1 (1/4)

HIPEC: Intraperitoneal hyperthermic chemotherapy.